Cost-Effectiveness of Fesoterodine and Tolterodine for the Treatment of Overactive Bladder with Urge Urinary Incontinence in Spain and Finland von Angulo, J, Rejas, J, Linden, K, Kvasz, M.G, Snedecor, S.J

Volltext

PUK11 UPDATED ECONOMIC ANALYSIS OF FESOTERODINE RELATIVE TO TOLTERODINE AND SOLIFENACIN FOR THE TREATMENT OF OVERACTIVE BLADDER: THE SWEDISH PERSPECTIVE von Lee, R, Snedecor, S.J, Kvasz, M.G, Trocio, J, Borgman, B

Volltext

PUK4 A Cost-Comparison Analysis of Treating Overactive Bladder (OAB) With Fesoterodine, Tolterodine or Solifenacin in Daily Clinical Practice in Spain von Sicras-Mainar, A, Rejas, J, Navarro-Artieda, R, Aguado-Jodar, A, Ruiz-Torrejón, A, Kvasz, M.G

Volltext

PUK19 Antimuscarinic Persistence Patterns in Newly Treated Patients With Overactive Bladder (OAB): Retrospective Comparative Analysis of Fesoterodine, Solifenacin and Tolterodine von Sicras-Mainar, A, Rejas, J, Navarro-Artieda, R, Ruiz-Torrejón, A, Aguado-Jodar, A, Kvasz, M.G

Volltext

PUK19 - Cost-Effectiveness of Fesoterodine and Tolterodine for the Treatment of Overactive Bladder with Urge Urinary Incontinence in Spain and Finland von Angulo, J., Rejas, J., Linden, K., Kvasz, M.G., Snedecor, S.J.

Volltext